Pyriproxifen Trial at Lahore Pakistan

50 %
50 %
Information about Pyriproxifen Trial at Lahore Pakistan
Education

Published on July 14, 2016

Author: luqmanmuhammad

Source: authorstream.com

slide 2: Basic Facts About Dengue • Dengue infection DFDHFDSS is major public health problem world wide 1 – Leading cause of morbidity mortality in 100 countries – 1/3 rd world population is at risk 50-100 M cases /Year • Vectors : Aedes aegypti Ae.albopictus 2 • Causal Organism : Flavi-virus 4-serotypes 23 • Pakistan : First outbreak 1994 at Karachi 2006 onward regular out breaks 4 • Treatment: No Specific Treatment symptomatic only 234 • Early recognition and supportive treatment minimize risk of complications 45 • Prevention : No vaccine Effective Vector Management is the best option 4 slide 3: Pyriproxyfen Is an insect growth regulator IGR belongs to the category of Juvenile hormone analogue 89 • Inhibits adult emergence 8910 • WHO recommended mosquito larvicide 1011 • Safer to non target organisms environment 911 • Recommended for use in potable containers 8910 slide 4: Conceptual Frame work slide 5: Rationale • In Pakistan Temephos is being used for many years 12 . • Continues selection pressure of Temephos may result in the development of Insecticide resistance 1213 . • Global Plan for Insecticide Resistance Management GPIRM recommends development of alternative vector control tools 14 . • This study was designed to determine efficacy and persistency of Pyriproxyfen IGR against Ae.aegypti as an alternate tool for vector control under IVM strategy. slide 6: Aims and Objectives slide 7: • Overall aim of the study is to save the community from dengue infections. • Key objective is to determine the Operational efficacy of Insect Growth Regulator Pyriproxyfen against dengue vector Ae.aegypti using its WHO recommended dosage 0.01mg/l a.i. slide 8: Materials Methods slide 9: Study Design • It is experimental study Duration of Study • August 2014 to December 2014 slide 10: Study Area District Lahore Punjab Pakistan 15 – Area of : 1722 km² – Latitude: B/w 31°15′ and 31°45′ N – Longitude: B/w 74°01′ and 74°39′ E – Altitude : at 217 m • Population : 7 million 16 • It is industrial hub shares about 20 of the industrial production of the country 17 slide 11: Collection of mosquito larvae • House to house surveys were made with the collaboration of Dengue vector surveillance teams of health department Lahore. • Larvae were collected brought to the entomological lab NIMRT LHR and colonized to get eggs and larvae for tests as per standard protocols 18. slide 12: Laboratory Trials • 6-buckets 2.5l capacity were filled with 2l tab water • 25 larvae 3 rd 4 th instars were added in each bucket • 4 buckets R1R2R3R4 were treated with Pyriproxyfen Predator 0.5WG at 0.01mg/l a.i. 4mg/bucket of product • 2 buckets C1C2 were kept as control slide 13: lab trials Continue • All buckets were kept in laboratory NIMRT LHR at – Temp 27 oc ±2 Humidity80±5 – covered with netting cloth • Larval Pupal mortality and adult emergence were recorded on daily basis till the emergence of all adults in control. • Tests were repeated with new lot of larvae on fortnightly basis slide 14: Simulated Field Trials • All test procedures were similar to the Lab trials except 20 of the water was replaced from all buckets on fortnightly basis before start of new test. slide 15: Field Trials • 6-Functional dessert coolers 80l water tank capacity were selected from samanabad townLHR. • 4 dessert coolers R1R2R3R4 were treated with Pyriproxyfen 0.01mg/l a.i • 2 dessert coolers C1C2 were kept as control • In every cooler ≈90 of water was evaporated daily and fresh tab water was refilled slide 16: Field trials continue • 1l water from each cooler exp control was brought to lab on every fortnight in disposable bottles. • In lab 200ml water was shifted to disposable cups of 250ml capacity. • 25 larvae 3 rd 4 th instar were added to each cup. • Cups were kept in lab similar to lab trials • Mortalities and adult emergence was noted • Tests were repeated on fortnightly basis slide 17: Data analysis • Data of adult emergence was combined from all replicates • EI was calculated using formula • EI 100XTotal larvae tested- total adults emerged/ Total larvae tested • Where control mortality was 5 to 20 corrected EI was calculated using mulla’s formula • EI 100-100T/C TEI in treatments C EI in control • Chi square analysis was applied to know the significance of the effectiveness slide 18: Results slide 19: Days of Treatment Dates of Data collectio n R1 R2 R3 R4 Total no. of larvae tested Total no. of adult emerged EI P-Value χ2 No. Tested Adult emerge No. Tested Adult emerge No. Tested Adult emerge No. Tested Adult emerge 1 01.08.14 to 10.08.14 25 0 25 0 25 0 25 0 100 0 100 − − 15 16.8.14 to 25.8.14 25 0 25 0 25 0 25 0 100 0 100 − − 30 31.8.14 to 09.9.14 25 0 25 0 25 0 25 0 100 0 100 − − 45 15.9.14 to 24.9.14 25 0 25 0 25 0 25 0 100 0 100 − − 60 30.9.14 to 09.10.14 25 0 25 0 25 0 25 0 100 0 100 − − 75 15.10.14 to 24.10.14 25 0 25 0 25 0 25 0 100 0 100 − − 90 30.10.14 to 08.11.14 25 0 25 0 25 0 25 0 100 0 100 − − 105 14.11.14 to 23.11.14 25 2 25 0 25 1 25 1 100 4 96 0.55 2.08 120 29.11.14 to 08.12.14 25 20 25 22 25 20 25 22 100 84 16 0.75 1.19 135 14.12.14 to 23.12.14 25 24 25 24 25 25 25 25 100 98 2 0.56 2.04 Laboratory trials indicating percentage of Emergence Inhibition of Adults EI Aedes aegypti from Day 1 to 135 days of treatment of Pyriproxyfen No of Mosquito larvae tested No of Adult Mosquito emerged R1-R4 Replicate 1 to 4 P-Value level of significance P0.05 P0.05 Non significance χ2 Chi-square value slide 20: -10 0 10 20 30 40 50 60 70 80 90 100 110 14-23 Dec14 29Nov-8 Dec14 14-23 Nov 14 30Oct-8 Nov14 15-24 Oct 14 30Sep-9 Oct14 15-24 Sep 14 31Aug-9 Sep 14 16-25 Aug 14 1-10 Aug 14 135 120 105 90 75 45 60 30 15 1 Adult Mosquitoes Emergence Number Treatment days Replicate 1 Replicate 2 Replicate 3 Replicate 4 Tolat Adult Emergence Laboratory trials indicating month wise Adult’s Emergence of Aedes aegypti from Day 1 to 135 of treatment of Pyriproxyfen slide 21: Days of Treatment Dates of Data collection R1 R2 R3 R4 Total no. of larvae tested Total no. of adult emerged EI P-Value χ2 No. Tested Adult emerge No. Tested Adult emerge No. Tested Adult emerge No. Tested Adult emerge 1 05.08.14 to 14.08.14 25 0 25 0 25 0 25 0 100 0 100 − − 15 20.08.14 to 29.08.14 25 0 25 0 25 0 25 0 100 0 100 − − 30 04.09.14 to 13.9.14 25 0 25 0 25 0 25 0 100 0 100 − − 45 19.09.14 to 28.09.14 25 0 25 0 25 0 25 0 100 0 100 − − 60 04.10.14 to 13.10.14 25 2 25 2 25 2 25 3 100 9 91 0.94 0.36 75 19.10.14 to 28.10.14 25 3 25 4 25 4 25 4 100 15 85 0.97 0.23 90 03.11.14 to 12.11.14 25 4 25 5 25 5 25 5 100 19 81 0.97 0.19 105 18.11.14 to 27.11.14 25 24 25 25 25 24 25 24 100 97 3 0.79 1.03 No of Mosquito larvae tested No of Adult Mosquito emerged R1-R4 Replicate 1 to 4 P-Value level of significance P0.05 P0.05 Non significance χ2 Chi-square value Simulated trials indicating Percentage Emergence Inhibition EI of Aedes aegypti from Day 1 to 105 of treatment of Pyriproxyfen slide 22: -10 0 10 20 30 40 50 60 70 80 90 100 110 18-27 Nov 14 19-28 Oct 14 20-29 Aug 14 3-12 Nov 14 4-13 Oct 14 19-28 Sep 14 4-13 Sep 14 5-14 Aug 14 105 90 75 45 60 30 15 1 Adult Mosquitoes Emergence Number Treatment days Replicate 1 Replicate 2 Replicate 3 Replicate 4 Tolat Adult Emergence Simulated trials indicating month wise Adult’s Emergence of Aedes aegypti from Day 1 to 105 of treatment of Pyriproxyfen slide 23: Days of Treatment Dates of Data collection R1 R2 R3 R4 Total no. of larvae tested Total no. of adult emerged EI P-Value χ2 No. Tested Adult emerge No. Tested Adult emerge No. Tested Adult emerge No. Tested Adult emerge 1 10.08.14 to 17.08.14 25 0 25 0 25 0 25 0 100 0 100 − − 15 25.08.14 to 01.09.14 25 0 25 0 25 0 25 0 100 0 100 − − 30 09.09.14 to 18.9.14 25 0 25 0 25 0 25 0 100 0 100 − − 45 24.9.14 to 03.10.14 25 0 25 1 25 0 25 0 100 1 99 0.38 3.03 60 09.10.14 to 18.10.14 25 23 25 23 25 24 25 23 100 93 1.1 0.92 0.46 75 24.10.14 to 02.11.14 25 24 25 24 25 24 25 24 100 96 4 1 0.00 Field trials of Aedes aegypti indicating percentage of Inhibition of Adult’s emergence EI from 1 to 105 days of treatment of Pyriproxyfen No of Mosquito larvae tested No of Adult Mosquito emerged corrected EI in control EI 6 R1-R4 Replicate 1 to 4 P-Value level of significance P0.05 P0.05 Non significance χ2 Chi-square value Field trials indicating percentage of Emergence Inhibition of Adults EI of Aedes aegypti from Day 1 to 75 of treatment of Pyriproxyfen slide 24: -10 0 10 20 30 40 50 60 70 80 90 100 110 24Oct-2 Nov 14 25Aug-1 Sep 14 9-18 Oct 14 24Sep-3 Oct 14 9-18 Sep 14 10-17 Aug 14 75 45 60 30 15 1 Adult Mosquitoes Emergence Number Treatment days Replicate 1 Replicate 2 Replicate 3 Replicate 4 Tolat Adult Emergence Field trials indicating month wise Adult’s Emergence of Aedes aegypti from Day 1 to 75 of treatment of Pyriproxyfen slide 25: Conclusions • Aedes aegypti is fully susceptible to WHO recommended dosage of Pyriproxyfen Predator 0.5 WG. • Persistency in Lab simulated and field trials supports its feasibility as an effective tool for dengue vector control as a part of “integrated vector management IVM” strategies. slide 26: Limitations of study • Due to shortage of time and resources study was limited to – Small area one town – Only one type of breeding place dessert cooler – Only one vector spp Aedes aegypti was tested – Only single dose 0.01 mg/L a.i was tested slide 27: References 1. Halstead SB. Dengue Haemorrhagic Fever- A Public Health Problem and a Field for Research. Bulletin of the World Health Organization. 1980 58 1: 1-2. 2. Gubler DJ. Epidemic Dengue/Dengue Hemorrhagic Fever as a Public Health Social and Economic Problem in the 21 st Century. Trends in Microbiology. 200210 2. 3. Alfonso et al. Phylogenetic Relationship of Dengue Virus Type 3 Isolated In Brazil and Paraguay and Global Evolutionary Divergence Dynamics. Virology Journal. 2012 9 124. Assessed on 1-12-2014. Online available at http://www.virologyj.com/content/9/1/124 4. Jahan N. and Sarwar SM. Field Evaluation of Lethal Ovitraps for the Control of Dengue Vectors in Lahore Pakistan. Pakistan Journal of Zoolology. 2013 452 pp.305-315. 5. Burney M.I. A report on the role of arthropod borne viruses in human diseases in Rawalpindi and Peshawar area. Pak. J. med. Res. 19961: 215-225. 6. World Health Organization. Handbook for integrated vector management. World Health Organization.2012 University of Florida Institute of Food and Agricultural Sciences. 7. World Health Organization. Operational Manual on the Application of Insecticides for Control of the Mosquito Vectors of Malaria and Other Diseases. WHO /CTD/VBC 96.1000 Rev 1chp6-11. Assessed on 04- 12-2014. Available at http://ebookbrowsee.net/who-ctd-vbc-96-1000-rev1-chp6-11-pdf-d294663338. 8. Mulla M. The future of insect growth regulators in vector control. Journal of the American Mosquito Control Association. 1995112 Pt 2:269-73. 9. WHO: Guidelines for drinking-water quality. World Health Organization. 2011. 10. World Health Organization. Guidelines on Environment Management of Dengue Vector in Pakistan. 2012 1. 11. World Health Organization. WHOPES recommended compounds and formulations for control of mosquito larvae. World Health Organization.2013. 12. Maharaj R. Global Trends in Insecticide Resistance and Impact on Disease Vector Control Measures. Open Access Insect Physiology 2011 3 pp. 27–33. 13. Araujo et al. The susceptibility of Aedes aegypti populations displaying temephos resistance to Bacillus thuringiensis israelensis: a basis for management. Parasites Vectors 2013 6:297. Assessed on 2-12-2014. Available at http://www.parasitesandvectors.com/content/pdf/1756-3305-6-297.pdf 14. World Health Organization. Golobal plan of insecticide resistance management in malaria vectors. World Health Organization.2012. slide 28: 15. Lahore My home City online available at http://www.ajmalbeig.addr.com/pak_lahore.htmIntroduction 16. Mazhar and Jamal. Temporal Population Growth of District Lahore. Journal of Scientific Research 2009391. 17. The Columbia Electronic Encyclopedia Copyright © 2004. Licensed from Columbia University Press. Online assessed on 22-1-2014. 18. Imam Hashmat Ghulamuddin Sofi Zarnigar and Aziz Seikh. "The basic rules and methods of mosquito rearing Aedes aegypti." Tropical parasitology . 2014 53 4:1. slide 29: Thanks

Add a comment

Related presentations

Related pages

Bio-efficacy and persistancy of Pyriproxyfen against Aedes ...

Background: Dengue is a serious public health issue of the current era. In the absence of any specific treatment and preventive vaccine, integrated vector management ...
Read more

www.researchgate.net

bio-efficacy and persistancy of pyriproxyfen against aedes aegypti: control trial at district lahore, punjab, pakistan muhammad asifmahmoodl , ...
Read more

Bio-Efficacy and Persistency of Pyriproxyfen against Aedes ...

Bio-Efficacy and Persistency of Pyriproxyfen against Aedes aegypti: A control Trial at District Lahore, Punjab, Pakistan
Read more

BIO-EFFICACY AND PERSISTANCY OF PYRIPROXYFEN AGAINST AEDES ...

official full-text paper (pdf): bio-efficacy and persistancy of pyriproxyfen against aedes aegypti: a control trial at district lahore, punjab, pakistan
Read more

PYRIPROXYFEN - paktradeinfo.com

PYRIPROXYFEN - PakTradeInfo.com, over 1,000,000 trade data importers and exporters. Business To Business (b2b) Trade Directory and Catalog. Trade leads. International ...
Read more

Open trials for Lahore Qalandar team on Monday – Daily ...

MULTAN (APP) - Open trials for the selection of Lahore Qalandar cricket team will be held at Multan cricket stadium on tomorrow (Monday). According to the source said ...
Read more

Pakistani Christians accused of lynching 'offered ...

Christian defendants facing trial over an alleged lynching were reportedly promised acquittal by a public official if they ... Lahore. Christian ... The Independent ...
Read more